Androgen receptors in hormone-dependent and castration-resistant prostate cancer

Pharmacology and Therapeutics

Volumn 140, Issue 3, 2013, Pages 223-238

  Shafi, Ayesha A ^a   Yen, Aihua E ^a   Weigel, Nancy L ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Abiraterone; Androgen receptor; Castration resistant prostate cancer; Enzalutamide (MDV3100); Prostate; Steroidogenesis

Indexed keywords

ABIRATERONE ACETATE; ANDROGEN RECEPTOR; BICALUTAMIDE; CYPROTERONE ACETATE; CYTOKINE; DEXAMETHASONE; ENZALUTAMIDE; FLUTAMIDE; GALETERONE; GOSERELIN; GROWTH FACTOR; LEUPRORELIN; NILUTAMIDE; ORTERONEL; PHOSPHOTRANSFERASE; PREDNISONE;

ANDROGEN DEPRIVATION THERAPY; ANDROGEN INSENSITIVITY SYNDROME; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; DIGITAL RECTAL EXAMINATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HORMONE BINDING; HUMAN; NONHUMAN; ORCHIECTOMY; POINT MUTATION; PRIORITY JOURNAL; PROSTATE EPITHELIUM; PROSTATECTOMY; PROTEIN FUNCTION; PROTEIN STRUCTURE; SALVAGE THERAPY; SIGNAL TRANSDUCTION; STEROID METABOLISM; STEROIDOGENESIS;

5Α-DHT; 5Α-DIHDYROTESTOSTERONE; AA; ABIRATERONE; ABIRATERONE ACETATE; ADT; ANDROGEN DEPRIVATION THERAPY; ANDROGEN RECEPTOR; ANDROGEN RESPONSE ELEMENT; AR; ARE; CAB; CASTRATION-RESISTANT PROSTATE CANCER; COMBINED ANDROGEN BLOCKADE; CRPC; DBD; DEHYDROEPIANDROSTERONE; DHEA; DNA-BINDING DOMAIN; ENZALUTAMIDE (MDV3100); FDA; FOOD AND DRUG ADMINISTRATION; H; HEAT SHOCK PROTEIN; HINGE; HSP; LBD; LHRH; LIGAND-BINDING DOMAIN; LUTEINIZING HORMONE-RELEASING HORMONE; N-TERMINAL DOMAIN; NON-STEROIDAL ANTI-ANDROGENS; NSAA; NTD; PCA; PROSTATE; PROSTATE CANCER; PROSTATE-SPECIFIC ANTIGEN; PSA; RADIATION THERAPY; RT; STEROIDOGENESIS; TMPRSS2; TRANSMEMBRANE PROTEASE SERINE 2; UGM; UROGENITAL SINUS MESENCHYME;

ANDROGENS; ANIMALS; HUMANS; MALE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, ANDROGEN;

EID: 84885468685     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2013.07.003     Document Type: Review

References (223)

1. T.T. Abd, M. Goodman, J. Hall, C.W. Ritenour, J.A. Petros, and F.F. Marshall Comparison of 12-core versus 8-core prostate biopsy: Multivariate analysis of large series of US veterans Urol J 77 2011 541 547
2. N. Agarwal, G. Sonpavde, and C.N. Sternberg Novel molecular targets for the therapy of castration-resistant prostate cancer Eur Urol 61 2012 950 960
3. I.U. Agoulnik, W.E.I. Bingman, M. Nakka, W. Li, Q. Wang, and M. Brown Target gene specific regulation of androgen receptor activity by p42/p44 MAPK Mol Endocrinol 22 2008 2420 2432
4. I.U. Agoulnik, A. Vaid, W.E.I. Bingman, H. Erdeme, A. Frolov, and C.L. Smith Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression Cancer Res 65 2005 7959 7967
5. I.U. Agoulnik, A. Vaid, M. Nakka, M. Alvarado, W.E.I. Bingman, and H. Erdem Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer Cancer Res 66 2006 10594 10602
6. I.U. Agoulnik, and N.L. Weigel Androgen receptor action in hormone-dependent and recurrent prostate cancer J Cell Biochem 99 2006 362 372
7. I.U. Agoulnik, and N.L. Weigel Androgen receptor coactivators and prostate cancer Adv Exp Med Biol 617 2008 245 255
8. I.U. Agoulnik, and N.L. Weigel Coactivator selective regulation of androgen receptor activity Steroids 74 2009 669 674
9. J. Ai, Y. Wang, J.A. Dar, J. Liu, L. Liu, and J.B. Nelson HDAC6 regulates androgen receptor hypersensitivity and nuclear localization via modulating Hsp90 acetylation in castration-resistant prostate cancer Mol Endocrinol 23 2009 1963 1972
10. H. Akaza, S. Hinotsu, M. Usami, Y. Arai, H. Kanetake, and S. Naito Study group for the combined androgen blockade therapy of prostate cancer. Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival Cancer 115 2009 3437 3445
11. R.J. Andersen, N.R. Mawji, J. Wang, G. Wang, S. Haim, and J.K. Myung Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor Cancer Cell 17 2010 535 546
12. J. Anderson The role of antiandrogen monotherapy in the treatment of prostate cancer BJU Int 91 2003 455 461
13. G. Attard, A.H. Reid, T.A. Yap, F. Raynaud, M. Dowsett, and S. Settatree Phase I clinical trial of a selective inhibitor of CYP17, abiralerone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven J Clin Oncol 26 2008 4563 4571
14. M.D. Balbas, M.J. Evans, D.J. Hosfield, J. Wongvipat, V.K. Arora, and P.A. Watson Overcoming mutation-based resistance to antiandrogens with rational drug design Elife 2 2013 e00499 e
15. A.H. Banham, J. Boddy, R. Launchbury, C. Han, H. Turley, and P.R. Malone Expression of the forkhead transcription factor FOXP1 is associated both with hypoxia inducible factors (HIFs) and the androgen receptor in prostate cancer but is not directly regulated by androgens or hypoxia Prostate 67 2007 1091 1098
16. C.E. Barbieri, S.C. Baca, M.S. Lawrence, F. Demichelis, M. Blattner, and J.P. Theurillat Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer Nat Genet 44 2012 685 689
17. D.A. Barron, and D.R. Rowley The reactive stroma microenvironment and prostate cancer progression Endocr Relat Cancer 19 2012 R187 R204
18. D.R. Bauman, S. Steckelbroeck, M.V. Williams, D.M. Peehl, and T.M. Penning Identification of the major oxidative 3alpha-hydroxysteroid dehydrogenase in human prostate that converts 5alpha-androstane-3alpha, 17beta-diol to 5alpha-dihydrotestosterone: A potential therapeutic target for androgen-dependent disease Mol Endocrinol 20 2006 444 458
19. J. Beilin, E.M. Ball, J.M. Favaloro, and J.D. Zajac Effect of the androgen receptor CAG repeat polymorphism on transcriptional activity: Specificity in prostate and non-prostate cell lines J Mol Endocrinol 25 2000 85 89
20. H. Beltran, R. Yelensky, G.M. Frampton, K. Park, S.R. Downing, and T.Y. MacDonald Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity Eur Urol 63 2013 920 926
21. D.R. Berthold, G.R. Pond, F. Soban, R. de Wit, M. Eisenberger, and I.F. Tannock Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study J Clin Oncol 26 2008 242 245
22. C.L. Bevan, S. Hoare, F. Claessens, D.M. Heery, and M.G. Parker The AF1 and AF2 domains of the androgen receptor interact with distinct regions of SRC1 Mol Cell Biol 19 1999 8383 8392
23. G.R. Blackledge, I.D. Cockshott, and B.J. Furr Casodex (bicalutamide): Overview of a new antiandrogen developed for the treatment of prostate cancer Eur Urol 31 1997 30 39
24. J.L. Boddy, S.B. Fox, C. Han, L. Campo, H. Turley, and S. Kanga The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1a, and the prolyl hydroxylases in human prostate cancer Clin Cancer Res 11 2005 7658 7663
25. C.E. Bohl, W. Gao, D.D. Miller, C.E. Bell, and J.T. Dalton Structural basis for antagonism and resistance of bicalutamide in prostate cancer Proc Natl Acad Sci U S A 102 2005 6201 6206
26. M. Bolla, D. Gonzalez, P. Warde, J.B. Dubois, R.O. Mirimanoff, and G. Storme Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin N Engl J Med 337 1997 295 300
27. L. Bubendorf, J. Kononen, P. Koivisto, P. Schraml, H. Moch, and T.C. Gasser Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays Cancer Res 59 1999 803 806
28. C. Cai, S. Chen, P. Ng, G.J. Bubley, P.S. Nelson, and E.A. Mostaghel Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors Cancer Res 71 2011 6503 6513
29. B.S. Carver, C. Chapinski, J. Wongvipat, H. Hieronymus, Y. Chen, and S. Chandarlapaty Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer Cancer Cell 19 2011 575 586
30. B.S. Carver, J. Tran, A. Gopalan, Z. Chen, S. Shaikh, and A. Carracedo Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate Nat Genet 41 2009 619 624
31. S.C. Chan, Y. Li, and S.M. Dehm Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal J Biol Chem 287 2012 19736 19749
32. K.H. Chang, R. Li, M. Papari-Zareei, L. Watumull, Y.D. Zhao, and R.J. Auchus Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer Proc Natl Acad Sci U S A 108 2011 13728 13733
33. Y. Chen, C.L. Sawyers, and H.I. Scher Targeting the androgen receptor pathway in prostate cancer Curr Opin Pharmacol 8 2008 440 448
34. C.D. Chen, D.S. Welsbie, C. Tran, S.H. Baek, R. Chen, and R. Vessella Molecular determinants of resistance to antiandrogen therapy Nat Med 10 2004 33 39
35. A.C. Chung, S. Zhou, L. Liao, J.C. Tien, N.M. Greenberg, and J. Xu Genetic ablation of the amplified-in-breast cancer 1 inhibits spontaneous prostate cancer progression in mice Cancer Res 67 2007 5965 5975
36. N.J. Clegg, J. Wongvipat, J.D. Joseph, C. Tran, S. Ouk, and A. Dilhas ARN-509: A novel antiandrogen for prostate cancer treatment Cancer Res 72 2012 1494 1503
37. J.M. Crook, C.J. O'Callaghan, G. Duncan, D.P. Dearnaley, C.S. Higano, E.M. Horwitz, E. Frymire, S. Malone, J. Chin, A. Nabid, P. Warde, T. Corbett, S. Angyalfi, S.L. Goldenberg, M.K. Gospodarowicz, F. Saad, J.P. Logue, E. Hall, P.F. Schellhammer, K. Ding, and L. Klotz Intermittent androgen suppression for rising PSA level after radiotherapy N Engl J Med 367 10 2012 895 903 10.1056/NEJMoa1201546 (Erratum in: N Engl J Med. 2012 Dec 6;367(23):2262. PubMed PMID: 22931259; PubMed Central PMCID:PMC3521033)
38. N. Craft, Y. Shostak, M. Carey, and C.L. Sawyers A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase Nat Med 5 1999 280 285 (Comment in Nat Med;5(3):264-265, 1999)
39. Z. Culig, A. Hobisch, G. Bartsch, and H. Klocker Androgen receptor - an update of mechanisms of action in prostate cancer Urol Res 28 2000 211 219
40. Z. Culig, A. Hobisch, M.V. Cronauer, C. Radmayr, J. Trapman, and A. Hittmair Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor Cancer Res 54 1994 5474 5478
41. G.R. Cunha, P.S. Cooke, and T. Kurita Role of stromal-epithelial interactions in hormonal responses Arch Histol Cytol 67 2004 417 434
42. A.V. D'Amico, M.H. Chen, A.A. Renshaw, M. Loffredo, and P.W. Kantoff Androgen suppression and radiation vs radiation alone for prostate cancer: A randomized trial JAMA 299 2008 289 295
43. M.S. Darshan, M.S. Loftus, M. Thadani-Mulero, B.P. Levy, D. Esciun, and X.K. Zhou Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer Cancer Res 71 2011 6019 6029
44. J.S. De Bono, C.J. Logothetis, A. Molina, K. Fizazi, S. North, and L. Chu Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 364 2011 1995 2005
45. G. de Lorenzo, G. Tortora, F.P. D'Armiento, G. de Rosa, S. Staibano, and R. Autorino Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer Clin Cancer Res 8 2002 3438 3444
46. J.D. Debes, L.J. Schmidt, H. Huang, and D.J. Tindall p300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6 Cancer Res 62 2002 5632 5636
47. S.M. Dehm, L.J. Schmidt, H.V. Heemers, R.L. Vessella, and D.J. Tindall Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance Cancer Res 68 2008 5469 5477
48. S.M. Dehm, and D.J. Tindall Alternatively spliced androgen receptor variants Endocr Relat Cancer 18 2011 R183 R196
49. J.W. Denham, A. Steigler, D.S. Lamb, D. Joseph, S. Turner, and J. Matthews Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-Year data from the TROG 96.01 randomised trial Lancet Oncol 12 2011 451 459
50. N.M. DeVore, and E.E. Scott Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001 Nature 482 2012 116 119
51. P.R. Dillard, M.F. Lin, and S.A. Khan Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol Mol Cell Endocrinol 295 2008 115 120
52. A.A. Donjacour, and G.R. Cunha Assessment of prostatic protein secretion in tissue recombinants made of urogenital sinus mesenchyme and urothelium from normal or androgen-insensitive mice Endocrinology 132 1993 2342 2350
53. J. Duff, and I.J. McEwan Mutation of histidine 874 in the androgen receptor ligand-binding domain leads to promiscuous ligand activation and altered p160 coactivator interactions Mol Endocrinol 19 2005 2943 2954
54. S.S. El Sheikh, H.M. Romanska, P. Abel, J. Domin, and N. Lalani Predictive value of PTEN and AR coexpression of sustained responsiveness to hormonal therapy in prostate cancer - a pilot study Neoplasia 10 2008 949 953
55. B.J. Feldman, and D. Feldman The development of androgen-independent prostate cancer Nat Rev Cancer 1 2001 34 45
56. R. Ferraldeschi, C. Pezaro, V. Karavasilis, and J. de Bono Abiraterone and novel antiandrogens: Overcoming castration resistance in prostate cancer Annu Rev Med 64 2013 1 13
57. K.H. Fischbeck, A. Lieberman, C.K. Bailey, A. Abel, and D.E. Merry Androgen receptor mutation in Kennedy's disease Philos Trans R Soc Lond B Biol Sci 354 1999 1075 1078
58. M.R. Freeman, B. Cinar, J. Kim, N.K. Mukhopadhyay, D. Di Vizio, and R.M. Adam Transit of hormonal and EGF receptor-dependent signals through cholesterol-rich membranes Steroids 72 2006 210 217
59. L. Gan, S. Chen, Y. Wang, A. Watahiki, L. Rohrer, and Z. Sun Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer Cancer Res 69 2009 8386 8394
60. J. Gao, J.T. Arnold, and J.T. Isaacs Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells Cancer Res 61 2001 5038 5044
61. E.P. Gelmann Molecular biology of the androgen receptor J Clin Oncol 20 2002 3001 3015
62. C. Geng, B. He, L. Xu, C.E. Barbieri, V.K. Eedunuri, and S.A. Chew Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover Proc Natl Acad Sci U S A 110 2013 6997 7002
63. E. Giovannucci, M.J. Stampfer, K. Krithivas, M. Brown, D. Dahl, and A. Brufsky The CAG repeat within the androgen receptor gene and its relationship to prostate cancer Proc Natl Acad Sci U S A 94 1997 3320 3323
64. V.J. Gnanapragasam, H.Y. Leung, A.S. Pulimood, D.E. Neal, and C.N. Robson Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer Br J Cancer 85 2001 1928 1936
65. B. Gottlieb, L.K. Beitel, A. Nadarajah, M. Paliouras, and M. Trifiro The androgen receptor gene mutations database: 2012 update Hum Mutat 33 2012 887 894
66. B. Gottlieb, L.K. Beitel, J.H. Wu, and M. Trifiro The androgen receptor gene mutations database (ARDB) Hum Mutat 23 2004 527 533
67. S.M. Green, E.A. Mostaghel, and P.S. Nelson Androgen action and metabolism in prostate cancer Mol Cell Endocrinol 360 2012 3 13
68. C.W. Gregory, K.G. Hamil, D. Kim, S.H. Hall, T.G. Pretlow, and J.L. Mohler Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes Cancer Res 58 1998 5718 5724
69. C.W. Gregory, R.T.J. Johnson, J.L. Mohler, F.S. French, and E.M. Wilson Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen Cancer Res 61 2001 2892 2898
70. Z. Guo, B. Dai, T. Jiang, K. Xu, Y. Xie, and O. Kim Regulation of androgen receptor activity by tyrosine phosphorylation Cancer Cell 10 2006 309 319
71. Y. Guo, S.C. Jacobs, and N. Kyprianou Down-regulation of protein and mRNA expression for transforming growth factor-beta (TGF-beta1) type 1 and type II receptors in human prostate cancer Int J Cancer 71 1997 573 579
72. Z. Guo, X. Yang, F. Sun, R. Jiang, D.E. Linn, and H. Chen A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth Cancer Res 69 2009 2305 2313
73. A. Gutierrez-Hartmann, D.L. Duval, and A.P. Bradford ETS transcription factors in endocrine systems Trends Endocrinol Metab 18 2007 150 158
74. G.E. Hanks, T.F. Pajak, A. Porter, D. Grignon, H. Brereton, and V. Venkatesan Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02 J Clin Oncol 21 2003 3972 3978
75. T. Hara, J. Kouno, K. Nakamura, M. Kusaka, and M. Yamaoka Possible role of adaptive mutation in resistance to antiandrogen in prostate cancer cells Prostate 65 2005 268 275
76. C.W. Hay, and I.J. McEwan The impact of point mutations in the human androgen receptor: Classification of mutations on the basis of transcriptional activity PLoS One 7 2012 e32514
77. S. He, C. Zhang, A.A. Shafi, M. Sequeira, J. Acquaviva, and J.C. Friedland Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression Int J Oncol 42 2013 35 43
78. H.V. Heemers, T.J. Sebo, J.D. Debes, K.M. Regan, K.A. Raclaw, and L.M. Murphy Androgen deprivation increases p300 expression in prostate cancer cells Cancer Res 67 2007 3422 3430
79. H.V. Heemers, and D.J. Tindall Androgen receptor (AR) coregulators: A diversity of functions converging on and regulating the AR transcriptional complex Endocr Rev 28 2007 778 808
80. C.A. Heinlein, and C. Chang Androgen receptor (AR) coregulators: An overview Endocr Rev 23 2002 175 200
81. C.A. Heinlein, and C. Chang The roles of androgen receptors and androgen-binding proteins in nongenomic androgen actions Mol Endocrinol 16 2002 2181 2187
82. A. Hobisch, I.E. Eder, T. Putz, W. Horninger, G. Bartsch, and H. Klocker Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor Cancer Res 58 1998 4640 4645
83. A. Hobisch, R. Ramoner, D. Fuchs, S. Godoy-Tundidor, G. Bartsch, and H. Klocker Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype Clin Cancer Res 7 2001 2941 2948
84. M.C. Hodgson, L.J. Shao, A. Frolov, R. Li, L.E. Peterson, and G. Ayala Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer Cancer Res 71 2011 572 582
85. Y. Homma, K. Kawabe, T. Tsukamoto, H. Yamanaka, K. Okada, and E. Okajima Epidemiologic survey of lower urinary tract symptoms in Asia and Australia using the international prostate symptom score Int J Urol 4 1997 40 46
86. E. Hörnberg, E.B. Ylitalo, S. Crnalic, H. Antti, P. Stattin, and A. Widmark Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival PLoS One 6 2011 e19059
87. J.S. Horoszewicz, S.S. Leong, T.M. Chu, Z.L. Wajsman, M. Friedman, and L. Papsidero The LNCaP cell line - a new model for studies on human prostatic carcinoma Prog Clin Biol Res 37 1980 115 132
88. R. Hu, T.A. Dunn, S. Wei, S. Isharwal, R.W. Veltri, and E. Humphreys Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer Cancer Res 69 2009 16 22
89. R. Hu, W.B. Isaacs, and J. Luo A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities Prostate 71 2011 1656 1667
90. I.A. Hughes, J.D. Davies, T.I. Bunch, V. Pasterski, K. Mastroyannopoulou, and J. MacDougall Androgen insensitivity syndrome Lancet 380 2012 1419 1428
91. I. Ianculescu, D.Y. Wu, K.D. Siegmund, and M.R. Stallcup Selective roles for cAMP response element-binding protein binding protein and p300 protein as coregulators for androgen-regulated gene expression in advanced prostate cancer cells J Biol Chem 287 2012 4000 4013
92. R.K. Jain Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy Science 307 2005 58 62
93. C.U. Jones, D. Hunt, D.G. McGowan, M.B. Amin, M.P. Chetner, and D.W. Bruner Radiotherapy and short-term androgen deprivation for localized prostate cancer N Engl J Med 365 2011 107 118
94. C.B. Kallen, J.T. Billheimer, S.A. Summers, S.E. Stayrook, M. Lewis, and I.J.F. Strauss Steroidogenic acute regulatory protein (StAR) is a sterol transfer protein J Biol Chem 273 1998 26285 26288
95. J.M. Kaminski, A.L. Hanion, D.L. Joon, M. Meistrich, P. Hachem, and A. Pollack Effect of sequencing of androgen deprivation and radiotherapy on prostate cancer growth Int J Radiat Oncol Biol Phys 57 2003 24 28
96. J.A. Kemppainen, E. Langley, C.I. Wong, K. Bobseine, W.R. Kelce, and E.M. Wilson Distinguishing androgen receptor agonists and antagonists: Distinct mechanisms of activation by medroxyprogesterone acetate and dihydrotestosterone Mol Endocrinol 13 1999 440 454
97. Y.S. Kim, S.V. Alarcon, S. Lee, M.J. Lee, G. Giaccone, and L. Neckers Update on Hsp90 inhibitors in clinical trial Curr Top Med Chem 9 2009 1479 1492
98. S. Koochekpour Androgen receptor signaling and mutations in prostate cancer Asian J Androl 12 2010 639 657
99. S. Kraus, D. Gioeli, T. Vomastek, V. Gordon, and M.J. Weber Receptor for activated C kinase 1 (RACK1) and Src regulate the tyrosine phosphorylation and function of the androgen receptor Cancer Res 66 2006 11047 11054
100. S. Kumar, M. Shelley, C. Harrison, B. Coles, T.J. Wilt, and M.D. Mason Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer Cochrane Database Syst Rev 2006 CD006019
101. K.P. Lai, S. Yamashita, C.K. Huang, S. Yeh, and C. Chang Loss of stromal androgen receptor leads to suppressed prostate tumourigenesis via modulation of pro-inflammatory cytokines/chemokines EMBO Mol Med 4 2012 791 807
102. J. Laverdière, A. Nabid, L.D. De Bedoya, A. Ebacher, A. Fortin, and C.S. Wang The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer J Urol 171 2004 1137 1140
103. D.A. Lawson, Y. Zong, S. Memarzadeh, L. Xin, J. Huang, and O.N. Whitte Basal epithelial stem cells are efficient targets for prostate cancer initiation Proc Natl Acad Sci U S A 107 2010 2610 2615
104. C.A. Lawton, K. Winter, K. Murray, M. Machtay, J.B. Mesic, and G.E. Hanks Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate Int J Radiat Oncol Biol Phys 49 2001 937 946
105. K.H. Leissner, and L.E. Tisell The weight of the human prostate Scand J Urol Nephrol 13 1979 137 142
106. C.G. Leon, J.A. Locke, H.H. Adomat, S.L. Etinger, A.L. Twiddy, and R.D. Neumann Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model Prostate 70 2010 390 400
107. L. Léotoing, M. Manin, D. Monté, S. Baron, Y. Communal, and C. Lours Crosstalk between androgen receptor and epidermal growth factor receptor-signalling pathways: a molecular switch for epithelial cell differentiation J Mol Endocrinol 39 2007 151 162
108. Y. Li, M. Alsagabi, D. Fan, G.S. Bova, A.H. Tewfik, and S.M. Dehm Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression Cancer Res 71 2011 2108 2117
109. C. Li, J. Ao, J. Fu, D.F. Lee, J. Xu, and D.M. Lonard Tumor-suppressor role for the SPOP ubiquitin ligase in signal-dependent proteolysis of the oncogenic co-activator SRC-3/AIB1 Oncogene 30 2011 4350 4364
110. Y. Li, T.H. Hwang, L.A. Oseth, A. Hauge, R.L. Vessella, and S.C. Schmechel AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression Oncogene 31 2012 4759 4767
111. S.J. Libertini, C.G. Tepper, V. Rodriguez, D.M. Asmuth, H.J. Kung, and M. Mudryj Evidence for calpain-mediated androgen receptor cleavage as a mechanism for androgen independence Cancer Res 67 2007 9001 9005
112. C. Lin, L. Yang, B. Tanasa, K. Hutt, B.G. Ju, and K. Ohgi Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer Cell 139 2009 1069 1083
113. J. Lindzey, M.V. Kumar, M. Grossmann, C. Young, and D.J. Tindall Molecular mechanisms of androgen action Vitam Horm 49 1994 383 432
114. W. Liu, C.C. Xie, Y. Zhu, T. Li, J. Sun, and Y. Cheng Homozygous deletions and recurrent amplifications implicate new genes involved in prostate cancer Neoplasia 10 2008 897 907
115. J.A. Locke, E.S. Guns, A.A. Lubik, H.H. Adomat, S.C. Hendy, and C.A. Wood Androgen levels increase by intratumoral de novo steroidogenesis during progressing of castration-resistant prostate cancer Cancer Res 68 2008 6407 6415
116. N.Z. Lu, S.E. Wardell, K.L. Burnstein, D. DeFranco, P.J. Fuller, and V. Giguere International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors Pharmacol Rev 58 2006 782 797
117. H. Ma, H. Hong, S.-M. Huang, R.A. Irvine, P. Webb, and P.J. Kushner Multiple signal input and output domains of the 160-kilodalton nuclear receptor coactivator proteins Mol Cell Biol 19 1999 6164 6173
118. N.P. Mahajan, Y. Liu, S. Majumder, M.R. Warren, C.E. Parker, and J.L. Mohler Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation Proc Natl Acad Sci U S A 104 2007 8438 8443
119. R.S. Mani, S.A. Tomlins, K. Callahan, A. Ghosh, M.K. Nyati, and S. Varambally Induced chromosomal proximity and gene fusions in prostate cancer Science 326 2009 1230
120. M. Manin, A. Martinez, B. van der Schueren, I. Reynaert, and C. Jean Acquisition of androgen-mediated expression of mouse vas deferens protein (MVDP) gene in cultured epithelial cells and in vas deferens during postnatal development J Androl 21 2000 641 650
121. C.E. Massie, A. Lynch, A. Ramos-Montoya, J. Boren, R. Stark, and L. Fazli The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis EMBO J 30 2011 2719 2733
122. I.K. Mellinghoff, I. Vivanco, A. Kwon, C. Tran, J. Wongvipat, and C.L. Sawyers HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability Cancer Cell 6 2004 517 527
123. S. Memarzadeh, L. Xin, D.J. Mulholland, A. Mansukhani, H. Wu, and M.A. Teitell Enhanced paracrine FGF10 expression promotes formation of multifocal prostate adenocarcinoma and an increase in epithelial androgen receptor Cancer Cell 12 2007 572 585
124. E.M. Messing, J. Manola, J. Yao, M. Kiernan, D. Crawford, and G. Wilding Immediate versis deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy Lancet Oncol 7 2006 472 479
125. A. Migliaccio, G. Castoria, and F. Auricchio Analysis of androgen receptor rapid actions in cellular signaling pathways: receptor/Src association Methods Mol Biol 776 2011 361 370
126. A. Migliaccio, L. Varricchio, A. De Falco, G. Castoria, C. Arra, and H. Yamaguchi Inhibition of the SH3 domain-mediated binding of Src to the androgen receptor and its effect on tumor growth Oncogene 26 2007 6619 6629
127. D.C. Miller, K.S. Hafez, A. Stewart, J.E. Montie, and J.T. Wei Prostate carcinoma presentation, diagnosis, and staging: an update from the National Cancer Data Base Cancer 98 2003 1169 1178
128. S. Minucci, and P.G. Pelicci Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer Nat Rev Cancer 6 2006 38 51
129. J. Mirosevich, J.M. Bentel, N. Zeps, S.L. Redmond, M.F. D'Antuono, and H.J. Dawkins Androgen receptor expression of proliferating basal and luminal cells in adult murine ventral prostate J Endocrinol 162 1999 341 350
130. N. Mitsiades, C.C. Sung, N. Schultz, D.C. Danila, B. He, and V.K. Eedunuri Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors Cancer Res 72 2012 6142 6152
131. H. Miyamoto, S.-H. Yeh, G. Wilding, and C. Chang Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells Proc Natl Acad Sci U S A 95 1998 7379 7384
132. J.L. Mohler, C.W. Gregory, O.H. Ford, D. Kim, C.M. Weaver, and P. Petrusz The androgen axis in recurrent prostate cancer Clin Cancer Res 10 2004 440 448
133. R.B. Montgomery, E.A. Mostaghel, R. Vessella, D.L. Hess, T.F. Kalhorn, and C.S. Higano Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth Cancer Res 68 2008 4447 4454
134. E.A. Mostaghel, S.T. Page, D.W. Lin, L. Fazli, I.M. Coleman, and L.D. True Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer Cancer Res 67 2007 5033 5041
135. V.A. Moyer, and U.S. Preventive Services Task Force Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement Ann Intern Med 157 2012 120 134
136. M. Nakka, I.U. Agoulnik, and N.L. Weigel Targeted disruption of the p160 coactivator interface of androgen receptor (AR) selectively inhibits AR activity in both androgen-dependent and castration-resistant AR-expressing prostate cancer cells Int J Biochem Cell Biol 45 2013 763 772
137. L.V. Nazareth, and N.L. Weigel Activation of the human androgen receptor through a protein kinase A signaling pathway J Biol Chem 271 1996 19900 19907
138. S. Niraula, K. Chi, and A.M. Joshua Beyond castration-defining future directions in the hormonal treatment of prostate cancer Horm Cancer 3 2012 3 13
139. Y. Niu, S. Altuwaijri, S. Yeh, K.P. Lai, S. Yu, and K.H. Chuang Targeting the stromal androgen receptor in primary prostate tumors at earlier stages Proc Natl Acad Sci U S A 105 2008 12188 12193
140. M.D. Nyquist, and S.M. Dehm Interplay between genomic alterations and androgen receptor signaling during prostate cancer development and progression Horm Cancer 2013 1 (Jan 2013 [Epub ahead of print])
141. A. O'Donnell, I. Judson, M. Dowsett, F. Raynaud, D. Dearnaley, and M. Mason Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer Br J Cancer 90 2004 2317 2325
142. D.M. Ornitz, and N. Itoh Fibroblast growth factors Genome Biol 2 2001 (REVIEWS3005)
143. C. Palmberg, P. Koivisto, E. Hyytinen, J. Isola, T. Visakorpi, and O.P. Kallioniemi Androgen receptor gene amplification in a recurrent prostate cancer after monotherapy with the nonsteroidal potent antiandrogen Casodex (bicalutamide) with a subsequent favorable response to maximal androgen blockade Eur Urol 31 1997 216 219
144. J.I. Park, M.G. Lee, K. Cho, B.J. Park, K.S. Chae, and D.S. Byun Transforming growth factor-beta1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-kappaB, JNK, and Ras signaling pathways Oncogene 22 2003 4314 4332
145. A.L. Potosky, B.A. Miller, P.C. Albertsen, and B.S. Kramer The role of increasing detection in the rising incidence of prostate cancer JAMA 273 1995 548 552
146. Prostate Cancer Trialists' Collaborative Group Maximum androgen blockade in advanced prostate cancer: An overview of the randomised trials Lancet 355 2000 1491 1498
147. J. Qin, S.P. Wu, C.J. Creighton, F. Dai, X. Xie, and C.M. Cheng COUP-TFII inhibits TGF-b-induced growth barrier to promote prostate tumorigenesis Nature 493 2013 236 240
148. Y. Qiu, L. Ravi, and H.J. Kung Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells Nature 393 1998 83 85
149. A.H. Reid, G. Attard, L. Ambroisine, G. Fisher, G. Kovacs, and D. Brewer Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer Br J Cancer 102 2010 678 684
150. J. Richards, A.C. Lim, C.W. Hay, A.E. Taylor, A. Wingate, and K. Nowakowska Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: A rationale for increasing abiraterone exposure or combining with MDV3100 Cancer Res 72 2012 2176 2182
151. M.O. Ripple, W.F. Henry, R.P. Rago, and G. Wilding Prooxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells J Natl Cancer Inst 89 1997 40 48
152. M. Roach, K. Bae, J. Speight, H.B. Wolkov, P. Rubin, and R.J. Lee Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: Long-term results of RTOG 8610 J Clin Oncol 26 2008 585 591
153. O.W. Rokhlin, R.B. Glover, N.V. Guseva, A.F. Taghiyev, K.G. Kohlgraf, and M.B. Cohen Mechanisms of cell death induced by histone deacetylase inhibitors in androgen receptor-positive prostate cancer cells Mol Cancer Res 4 2006 113 123
154. A.K. Roy, Y. Lavrovsky, C.S. Song, S. Chen, M.H. Jung, and N.K. Velu Regulation of androgen action Vitam Horm 55 1999 309 352
155. C.J. Ryan Secondary hormonal manipulations in prostate cancer Hematol Oncol Clin North Am 20 2006 925 934
156. C.J. Ryan, M.R. Smith, J.S. De Bono, A. Molina, C.J. Logothetis, and P. de Souza Abiraterone in metastatic prostate cancer without previous chemotherapy N Engl J Med 368 2013 138 148
157. J.S. Sack, K.F. Kish, C. Wang, R.M. Attar, S.E. Kiefer, and Y. An Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone Proc Natl Acad Sci U S A 98 2001 4904 4909
158. D.J. Samson, J. Seidenfeld, B. Schmitt, V. Hasselblad, P.C. Albertsen, and C.L. Bennett Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma Cancer 95 2002 361 376
159. A.V. Schally Luteinizing hormone-releasing hormone analogs: Their impact on the control of tumorigenesis Peptides 20 1999 1247 1262
160. H.I. Scher, G. Buchanan, W. Gerald, L.M. Butler, and W.D. Tilley Targeting the androgen receptor: Improving outcomes for castration-resistant prostate cancer Endocr Relat Cancer 11 2004 459 476
161. H.I. Scher, K. Fizazi, and F. Saad Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the phase III AFFIRM study J Clin Oncol 30 2012 (Abstract LBA1-(ASCO Genitourinary Cancers Symposium Abstracts))
162. H.I. Scher, and C.L. Sawyers Biology of progressive, castration-resistant prostate cancer: Directed therapies targeting the androgen-receptor signaling axis J Clin Oncol 23 2005 8253 8261
163. F.H. Schröder, K.H. Kurth, S.D. Fosså, W. Hoekstra, P.P. Karthaus, and M. Debois Early versus delayed endocrine treatment of pN1-3 MO prostate cancer without local treatment of the primary tumor: results of European Organisation for the Research and Treatment of Cancer 30846 - a phase III study J Urol 172 2004 923 927
164. A. Sen, K. O'Malley, Z. Wang, G.V. Raj, D.B. DeFranco, and S.R. Hammes Paxillin regulates androgen- and epidermal growth factor-induced MAPK signaling and cell proliferation in prostate cancer cells J Biol Chem 285 2010 28787 28795
165. B. Seruga, A. Ocana, and I.F. Tannock Drug resistance in metastatic castration-resistant prostate cancer Nat Rev Clin Oncol 8 2011 12 23
166. A.A. Shafi, M.B. Cox, and N.L. Weigel Androgen receptor splice variants are resistant to inhibitors of Hsp90 and FKBP52, which alter androgen receptor activity and expression Steroids 78 6 2013 548 554
167. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2013 CA Cancer J Clin 63 2013 11 30
168. S. Signoretti, R. Montironi, J. Manola, A. Altimari, C. Tam, and G. Bubley Her-2-neu expression and progression toward androgen independence in human prostate cancer J Natl Cancer Inst 92 2000 1918 1925
169. D.B. Solit, and N. Rosen Hsp90: A novel target for cancer therapy Curr Top Med Chem 6 2006 1205 1214
170. K. Song, H. Wang, T.L. Krebs, B. Wang, T.J. Kelley, and D. Danielpour DHT selectively reverses Smad3-mediated/TGF-beta-induced responses through transcriptional down-regulation of Smad3 in prostate epithelial cells Mol Endocrinol 24 2010 2019 2029
171. M.B. Sporn, and A.B. Roberts Transforming growth factor-beta: Recent progress and new challenges J Cell Biol 119 1992 1017 1021
172. K. Steketee, L. Timmerman, A.C. Ziel-van der Made, P. Doesburg, A.O. Brinkmann, and J. Trapman Broadened ligand responsiveness of androgen receptor mutants obtained by random amino acid substitution of H874 and mutation hot spot T877 in prostate cancer Int J Cancer 100 2002 309 317
173. G.D. Stewart, J. Nanda, E. Katz, K.J. Bowman, J.G. Christie, and D.J. Brown DNA strand breaks and hypoxia response inhibition mediate the radiosensitisation effect of nitric oxide donors on prostate cancer under varying oxygen conditions Biochem Pharmacol 81 2011 203 210
174. C. Sun, A. Dobi, A. Mohamed, H. Li, R.L. Thangapazham, and B. Furusato TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation Oncogene 27 2008 5348 5353
175. S. Sun, C.C. Sprenger, R.L. Vessella, K. Haugk, K. Soriano, and E.A. Mostaghei Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant J Clin Invest 120 2010 2715 2730
176. H. Suzuki, K. Akakura, A. Komiya, S. Aida, S. Akimoto, and J. Shimazaki Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome Prostate 29 1996 153 158
177. I.F. Tannock, R. de Wit, W.R. Bersch, J. Horti, A. Pluzanska, and K.N. Chi Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512
178. M.E. Taplin, G.J. Bubley, Y.J. Ko, E.J. Small, M. Upton, and B. Rajeshkumar Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist Cancer Res 59 1999 2511 2515
179. O. Tatarov, T.J. Mitchell, M. Seywright, H.Y. Leung, V.G. Brunton, and J. Edwards SRC family kinase activity is up-regulated in hormone-refractory prostate cancer Clin Cancer Res 15 2009 3540 3549
180. B.S. Taylor, N. Schultz, H. Hieronymus, A. Gopalan, Y. Xiao, and B.S. Carver Integrative genomic profiling of human prostate cancer Cancer Cell 18 2010 11 22
181. J. Thompson, F. Saatcioglu, O.A. Jänne, and J.J. Palvimo Disrupted amino- and carboxyl-terminal interactions of the androgen receptor are linked to androgen insensitivity Mol Endocrinol 15 2001 923 935
182. L.H. Toledo-Pereyra Discovery in surgical investigation: The essence of Charles Brenton Huggins J Invest Surg 14 2001 251 252
183. S.A. Tomlins, B. Laxman, S. Varambally, X. Cao, J. Yu, and B.E. Helgeson Role of the TMPRSS2-ERG gene fusion in prostate cancer Neoplasia 10 2008 177 188
184. S.A. Tomlins, D.R. Rhodes, S. Perner, S.M. Dhanasekaran, R. Mehra, and X.W. Sun Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer Science 310 2005 644 648
185. C. Tran, S. Ouk, N.J. Clegg, Y. Chen, P.A. Watson, and V. Arora Development of a second-generation antiandrogen for treatment of advanced prostate cancer Science 324 2009 787 790
186. J.J. Tu, S. Rohan, J. Kao, N. Kitabayashi, S. Mathew, and Y.T. Chen Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: Frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues Mod Pathol 20 2007 921 928
187. T. Ueda, N.R. Mawji, N. Bruchovsky, and M.D. Sadar Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells J Biol Chem 277 2002 38087 38094
188. D.J. van de Wijngaart, M. Molier, S.J. Lusher, R. Hersmus, G. Jenster, and J. Trapman Systematic structure-function analysis of androgen receptor Leu701 mutants explains the properties of the prostate cancer mutant L701H J Biol Chem 285 2010 5097 5105
189. M. van der Deen, J. Akech, T. Wang, T.J. FitzGerald, D.C. Altieri, and L.R. Languino The cancer-related Runx2 protein enhances cell growth and responses to androgen and TGFbeta in prostate cancer cells J Cell Biochem 109 2010 828 837
190. J. Veldscholte, C. Ris-Stalpers, G.G.J.M. Kuiper, G. Jenster, C. Berrevoets, and E. Claassen A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to antiandrogens Biochem Biophys Res Commun 173 1990 534 540
191. T. Visakorpi, E. Hyytinen, P. Koivisto, M. Tanner, R. Keinanen, and C. Palmberg In vivo amplification of the androgen receptor gene and progression of human prostate cancer Nat Genet 9 1995 401 406
192. K.K. Waltering, M.A. Helenius, B. Sahu, V. Manni, M.J. Linja, and O.A. Jänne Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens Cancer Res 69 2009 8141 8149
193. J. Wang, Y. Cai, C. Ren, and M. Ittmann Expression of variant TMPRSS2/ERG fusion mRNAs is associated with aggressive prostate cancer Cancer Res 66 2006 8347 8351
194. J. Wang, Y. Cai, W. Yu, C. Ren, D.M. Spencer, and M. Ittmann Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts Cancer Res 68 2008 8516 8524
195. Q. Wang, J.S. Carroll, and M. Brown Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking Mol Cell 19 2005 631 642
196. S. Wang, J. Gao, Q. Lei, N. Rozengurt, C. Pritchard, and J. Jiao Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer Cancer Cell 4 2003 209 221
197. X. Wang, J.M. Kruithof-de, K.D. Economides, D. Walker, H. Yu, and M.V. Halili A luminal epithelial stem cell that is a cell of origin for prostate cancer Nature 461 2009 495 500
198. Q. Wang, W. Li, X.S. Liu, J.S. Carroll, O.A. Jänne, and E.K. Keeton A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth Mol Cell 27 2007 380 392
199. Q. Wang, W. Li, Y. Zhang, X. Yuan, K. Xu, and J. Yu Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer Cell 138 2009 245 256
200. Z.A. Wang, A. Mitrofanova, S.K. Bergren, C. Abate-Shen, R.D. Cardiff, and A. Califano Lineage analysis of basal epithelial cells reveals their unexpected plasticity and supports a cell-of-origin model for prostate cancer heterogeneity Nat Cell Biol 15 2013 274 283
201. P.A. Watson, Y.F. Chen, M.D. Balbas, J. Wongvipat, N.D. Socci, and A. Viale Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor Proc Natl Acad Sci U S A 107 2010 16759 16765
202. C.M. Wilson, and M.J. McPhaul A and B forms of the androgen receptor are present in human genital skin fibroblasts Proc Natl Acad Sci U S A 91 1994 1234 1238
203. M.P. Wirth, O.W. Hakenberg, and M. Froehner Antiandrogens in the treatment of prostate cancer Eur Urol 51 2007 306 313
204. I.M. Wolf, M.D. Heitzer, M. Grubisha, and D.B. DeFranco Coactivators and nuclear receptor transactivation J Cell Biol 104 2008 1580 1586
205. M. Yamaoka, T. Hara, T. Hitaka, T. Kaku, T. Takeuchi, and J. Takahashi Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: Effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys J Steroid Biochem Mol Biol 129 2012 115 128
206. J. Yan, H. Erdem, Y. Cai, G. Ayala, M. Ittmann, and L. Yu-Lee Steroid receptor coactivator-3/AIB1 promotes cell migration and invasiveness through focal adhesion turnover and matrix metalloproteinase expression Cancer Res 68 2008 5460 5468
207. X. Yang, Z. Guo, F. Sun, W. Li, A. Alfano, and H. Shimelis Novel membrane-associated androgen receptor splice variant potentiates proliferative and survival responses in prostate cancer cells J Biol Chem 286 2011 36152 36160
208. J.C. Yang, J.H. Ok, J.E. Busby, A.D. Borowsky, H.J. Kung, and C.P. Evans Aberrant activation of androgen receptor in a new neuropeptide-autocrine model of androgen-insensitive prostate cancer Cancer Res 69 2009 151 160
209. S. Yeh, and C. Chang Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells Proc Natl Acad Sci U S A 93 1996 5517 5521
210. T. Yoshida, H. Kinoshita, T. Segawa, E. Nakamura, T. Inoue, and Y. Shimizu Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient Cancer Res 65 2005 9611 9666
211. M. Yoshimoto, A.M. Joshua, I.W. Cunha, R.A. Coudry, F.P. Fonseca, and O. Ludkovski Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome Mod Pathol 21 2008 1451 1460
212. S.Q. Yu, K.P. Lai, S.J. Xia, H.C. Chang, C. Chang, and S. Yeh The diverse and contrasting effects of using human prostate cancer cell lines to study androgen receptor roles in prostate cancer Asian J Androl 11 2009 39 48
213. J. Yu, J. Yu, R.S. Mani, Q. Cao, C.J. Brenner, and X. Cao An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression Cancer Cell 17 2010 443 454
214. O.L. Zegarra-Moro, L.J. Schmidt, H. Huang, and D.J. Tindall Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells Cancer Res 62 2002 1008 1013
215. X. Zhang, C. Morrissey, S. Sun, M. Ketchandji, P.S. Nelson, and L.D. True Androgen receptor variants occur frequently in castration resistant prostate cancer metastases PLoS One 6 2011 e27970
216. S. Zhang, B. Pavlovitz, J. Tull, Y. Wang, F.M. Deng, and C. Fuller Detection of TMPRSS2 gene deletions and translocations in carcinoma, intraepithelial neoplasia, and normal epithelium of the prostate by direct fluorescence in situ hybridization Diagn Mol Pathol 19 2010 151 156
217. H.J. Zhou, J. Yan, W. Luo, G. Ayala, S.H. Lin, and H. Erdem SRC-3 is required for prostate cancer cell proliferation and survival Cancer Res 65 2005 7976 7983
218. M.L. Zhu, C.M. Horbinski, M. Garzotto, D.Z. Qian, T.M. Beer, and N. Kyprianou Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer Cancer Res 70 2010 7992 8002
219. M.L. Zhu, and N. Kyprianou Androgen receptor and growth factor signaling cross-talk in prostate cancer cells Endocr Relat Cancer 15 2008 841 849
220. A.L. Zietman, B.M. Nakfoor, E.A. Prince, and L.E. Gerweck The effect of androgen deprivation and radiation therapy on an androgen-sensitive murine tumor: An in vitro and in vivo study Cancer J Sci Am 3 1997 31 36
221. A.L. Zietman, E.A. Prince, B.M. Nakfoor, and W.U. Shipley Neoadjuvant androgen suppression with radiation in the management of locally advanced adenocarcinoma of the prostate: Experimental and clinical results Urol J 49 1997 74 83
222. Y. Zong, L. Xin, A.S. Goldstein, D.A. Lawson, M.A. Teitell, and O.N. Witte ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells Proc Natl Acad Sci U S A 106 2009 12465 12470
223. J.X. Zou, Z. Zhong, X.B. Shi, C.G. Tepper, R.W. deVere White, and H.J. Kung ACTR/AIB1/SRC-3 and androgen receptor control prostate cancer cell proliferation and tumor growth through direct control of cell cycle genes Prostate 66 2006 1474 1486